Here are 1-3 brief analogies for Unicycive Therapeutics (UNCY):

• Amgen for kidney diseases.

• Vertex Pharmaceuticals for kidney diseases.

• Renazorb: A therapy being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease.
• UNI 494: A therapy being developed for the treatment of acute kidney injury.

Unicycive Therapeutics (UNCY) is a biotechnology company engaged in the development of novel therapies for kidney diseases. As the company's products, Renazorb and UNI-494, are currently in the development phase (awaiting regulatory approval or in pre-clinical studies), Unicycive Therapeutics does not yet have commercialized products generating significant sales. Therefore, the company does not currently have major commercial customers.

• Thermo Fisher Scientific Inc. (TMO)
• SK Inc. (034730)

Shalabh Gupta, MD Chief Executive Officer, President, and Chairman of the Board of Directors

Shalabh Gupta, MD, is the founder of Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta founded and served as Chief Executive Officer of Biocycive Inc. He also held a commercial strategy role at Genentech, Inc., and worked as an equity researcher covering US pharmaceutical companies at UBS Investment Bank and biotechnology companies at Rodman & Renshaw. Before his roles in business and finance, Dr. Gupta was an attending physician at NYU Medical Center and a clinical faculty member at the NYU School of Medicine.

John Townsend Chief Financial Officer

John Townsend is the Chief Financial Officer at Unicycive Therapeutics Inc. He previously served as Vice President of Finance and Chief Accounting Officer in a consulting capacity for Unicycive. Mr. Townsend has over 25 years of public and private company experience across industries including biotechnology, medical devices, and high-tech electronics manufacturing. Before joining Unicycive, he worked at Guardion Health Sciences from 2016 to 2020 and Cytori Therapeutics, Inc. from 2005 until 2015. He started his career at Deloitte.

Pramod Gupta, PhD Executive Vice President, Pharmaceutical & Business Operations

Pramod Gupta, PhD, serves as the Executive Vice President of Pharmaceutical & Business Operations at Unicycive Therapeutics Inc. His prior experience includes roles as SVP of Pharmaceutical Operations at Spectrum Pharmaceuticals, Global VP at Bausch & Lomb, Senior Director of R&D at Baxter Healthcare, Director of R&D at TAP Pharmaceuticals (a joint venture of Abbott & Takeda), and R&D Project Leader at Abbott Pharmaceuticals. Dr. Gupta has developed, received regulatory approvals for, and commercialized over 40 pharmaceutical products.

Douglas Jermasek, MBA Executive Vice President, Corporate Strategy

Douglas Jermasek joined Unicycive in 2021 as Executive Vice President, Corporate Strategy. He is a biopharmaceutical executive with over 25 years of commercial leadership experience in both U.S. and international markets. Most recently, he served as Senior Vice President, Marketing and Strategy at Akebia Therapeutics, following its merger with Keryx Biopharmaceuticals.

Guru Reddy, Ph.D. Vice President of Preclinical R&D

Guru Reddy, PhD, joined Unicycive in 2022 as Vice President of Preclinical R&D. He brings over 25 years of R&D experience in the biopharmaceutical industry. Prior to Unicycive, Dr. Reddy worked at Spectrum Pharmaceuticals for 15 years, where he held R&D roles with increasing responsibilities, most recently as Vice President of Preclinical R&D. At Spectrum Pharmaceuticals, he was responsible for the preclinical development and clinical pharmacology of a large product pipeline, leading to multiple NDA submissions and full regulatory approval of 4 drugs from the US FDA.

Unicycive Therapeutics, Inc. (UNCY), a biotechnology company focused on developing novel therapies for kidney diseases, faces several key risks inherent to the pharmaceutical and biotechnology industries.

Key Risks to the Business:

1. Clinical Trial and Regulatory Risks: The success and valuation of Unicycive Therapeutics are heavily dependent on the outcomes of its clinical trials and the ability to secure regulatory approvals for its product candidates, Renazorb (also known as oxylanthanum carbonate or OLC) and UNI-494. Clinical trials are lengthy, expensive, and have uncertain outcomes, with results from earlier studies not always predictive of future trial success. The company has already faced a Complete Response Letter (CRL) from the FDA for OLC due to compliance deficiencies at a third-party manufacturing vendor, which delayed its approval process. There is no guarantee that the FDA will grant marketing approval even after addressing such issues, and additional studies or inspections may be required, extending timelines and increasing costs.
2. Cash Burn and Dilution: As a pre-revenue clinical-stage biotechnology company, Unicycive Therapeutics consistently incurs operating losses due to ongoing research and development (R&D) expenses. This necessitates a continuous need for additional funding, which is typically secured through equity raises. Such equity issuances can dilute the ownership stake of existing shareholders, potentially pressuring the stock price. While the company has reported a cash runway into 2027, the substantial cash burn highlights the ongoing financial risk until products achieve commercialization and generate revenue.
3. Intense Competition: Unicycive operates in a highly competitive landscape within the kidney disease treatment market. For Renazorb (OLC), it competes with established phosphate binders such as Renvela (AstraZeneca) and Fosrenol (Chugai), as well as newer therapies being developed by other pharmaceutical and biotech companies. The field of kidney disease therapies is dynamic, with other companies continuously developing innovative treatments, which could impact Unicycive's market share and profitability if their products are approved.

For Unicycive Therapeutics' main products, the addressable markets are as follows:

• Renazorb (treatment of hyperphosphatemia):
  • The global hyperphosphatemia treatment market was valued at approximately $1.46 billion in 2024 and is projected to reach $2.94 billion by 2033, with a compound annual growth rate (CAGR) of 8.1% from 2026 to 2033.
  • In 2023, the global market opportunity for treating hyperphosphatemia was projected to be in excess of $2.5 billion, with the United States accounting for over $1 billion of that total.
  • The hyperphosphatemia treatment market in the U.S. alone exceeds $1 billion, and is more than double that worldwide.
• UNI 494 (treatment of acute kidney injury):
  • The global acute kidney injury (AKI) market size was approximately $6.23 billion in 2022 and is anticipated to grow significantly through 2034.
  • The global acute kidney injury treatment market was valued at $3.6 billion in 2024 and is projected to reach over $8.2 billion by 2035, at a CAGR of 7.8% from 2025 to 2035.
  • The acute kidney injury market size is expected to grow from $5.72 billion in 2025 to $6.09 billion in 2026 at a CAGR of 6.5%, and further to $7.78 billion in 2030 at a CAGR of 6.3%.
  • In 2022, the United States had the largest market size for Acute Kidney Injury.

Unicycive Therapeutics (UNCY) is poised for future revenue growth over the next 2-3 years, driven primarily by the anticipated commercialization of its lead product, Renazorb, and the continued advancement of its pipeline candidate, UNI-494. Analysts project significant revenue growth for the company, with forecasts indicating an annual increase of 37.5% in revenue.

Drivers of Future Revenue Growth:

1. U.S. Commercial Launch and Market Penetration of Renazorb: The primary driver of near-term revenue growth is the potential U.S. Food and Drug Administration (FDA) approval and subsequent commercial launch of oxylanthanum carbonate (OLC), marketed as Renazorb. The FDA accepted the New Drug Application (NDA) resubmission for Renazorb in January 2026, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026. If approved, Renazorb will target the hyperphosphatemia market in patients with chronic kidney disease, which represents a U.S. market opportunity exceeding $1 billion. Its proprietary nanoparticle technology offers a differentiated product profile with potentially fewer and smaller pills, addressing a significant unmet patient need for improved adherence.
2. International Expansion and Partnerships for Renazorb: Beyond the U.S. market, Unicycive is actively pursuing global expansion for Renazorb. The company has already secured an exclusive license agreement with Lotus Pharmaceutical for the development and commercialization of Renazorb in the Republic of Korea, which includes upfront payments, milestone payments, and tiered royalties. Unicycive is also in discussions with potential partners for other key geographies in Asia and Europe, indicating further opportunities for licensing revenue and royalties from new markets.
3. Advancement and Potential Commercialization of UNI-494 for Acute Kidney Injury (AKI) and Delayed Graft Function (DGF): UNI-494, Unicycive's investigational therapy for acute kidney injury, represents a significant pipeline-driven revenue opportunity. The company successfully completed its Phase 1 study for UNI-494, demonstrating favorable tolerability, fast absorption, and rapid metabolization. Unicycive plans to engage with the FDA to discuss Phase 1 results and the design of a potential Phase 2 study. Furthermore, UNI-494 has been granted Orphan Drug Designation by the FDA for the prevention of Delayed Graft Function after kidney transplantation. Given the absence of any FDA-approved drugs for AKI, UNI-494 addresses a substantial unmet medical need, positioning it for potential future revenue generation if clinical development continues to progress positively.
4. Revenue from Existing Licensing Agreements: Unicycive already benefits from existing licensing agreements, such as the one with Lotus Pharmaceutical for Renazorb in the Republic of Korea. These agreements provide ongoing revenue streams through milestone payments based on regulatory and commercial achievements, as well as tiered royalties on future sales, contributing to the company's overall financial growth.

Share Issuance

• Unicycive Therapeutics completed an Initial Public Offering (IPO) in July 2021, raising $25 million by issuing 4,600,000 shares at a price between $5.00 and $6.00 per share.
• In March 2024, the company announced a private placement that resulted in gross proceeds of $50 million through the sale of 50,000 shares of its Series B Convertible Preferred Stock at an offering price of $1,000 per share.
• On November 14, 2025, Unicycive Therapeutics amended its at-the-market (ATM) equity program, doubling its potential offering capacity from $50 million to $100 million.

Inbound Investments

• A $50 million private placement closed in March 2024, led by new investors Octagon Capital and Great Point Partners, LLC, with participation from new and existing healthcare institutional investors.
• Institutional investors collectively own a significant 40.42% of the company, representing approximately $37 million as of mid-November 2025.
• Major institutional shareholders include Vivo Capital LLC and Vanguard Group Inc.

Capital Expenditures

• Capital expenditures for the company were $0.03 million in 2021, $0.00 million in 2022, $0.01 million in 2023, and $0.07 million in 2024.